mebendazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anthelminthics, tiabendazole derivatives | 1641 | 31431-39-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| BA (Bioavailability) | 22 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 15 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.09 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 28, 1974 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Exposure during pregnancy | 116.26 | 49.11 | 40 | 334 | 108172 | 46577516 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | P02CA01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Benzimidazole derivatives |
| ATC | P02CA51 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Benzimidazole derivatives |
| FDA EPC | N0000175481 | Anthelmintic |
| MeSH PA | D000871 | Anthelmintics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D050256 | Antimitotic Agents |
| MeSH PA | D000969 | Antinematodal Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D050257 | Tubulin Modulators |
| CHEBI has role | CHEBI:35444 | antinematodals |
| CHEBI has role | CHEBI:60832 | tubulin modulators |
| CHEBI has role | CHEBI:61951 | microtubule destabilising role |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ascariasis | indication | 2435008 | DOID:456 |
| Trichuriasis | indication | 3752003 | |
| Enterobiasis | indication | 266162007 | |
| Ancylostoma Duodenale Infection | indication | ||
| Necator Americanus Infection | indication | ||
| Infection by Gnathostoma | off-label use | 44086001 | DOID:11379 |
| Capillaria infection | off-label use | 52979002 | DOID:12474 |
| Echinococcus granulosus infection | off-label use | 75006000 | DOID:1495 |
| Echinococcus multilocularis | off-label use | 86648009 | |
| Infection by larvae of Trichinella spiralis | off-label use | 88264003 | |
| Angiostrongyliasis due to Angiostrongylus cantonensis | off-label use | ||
| Angiostrongyliasis due to Angiostrongylus costaricensis | off-label use | ||
| Disease of liver | contraindication | 235856003 | DOID:409 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.61 | acidic |
| pKa2 | 13.2 | acidic |
| pKa3 | 2.93 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Kinase | Ki | 5.34 | CHEMBL | |||||
| Vascular endothelial growth factor receptor 2 | Kinase | IC50 | 5.44 | CHEMBL | |||||
| Tubulin | Structural | INHIBITOR | CHEMBL | CHEMBL | |||||
| Tubulin | Structural | INHIBITOR | CHEMBL | CHEMBL | |||||
| Calmodulin-domain protein kinase 1 | Kinase | IC50 | 6.17 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019270 | VUID |
| N0000147469 | NUI |
| D00368 | KEGG_DRUG |
| 4019270 | VANDF |
| C0025023 | UMLSCUI |
| CHEBI:6704 | CHEBI |
| CHEMBL685 | ChEMBL_ID |
| D008463 | MESH_DESCRIPTOR_UI |
| DB00643 | DRUGBANK_ID |
| 2942 | INN_ID |
| 81G6I5V05I | UNII |
| 4030 | PUBCHEM_CID |
| 202972 | RXNORM |
| 1672 | MMSL |
| 5026 | MMSL |
| 789 | MMSL |
| d00154 | MMSL |
| 002987 | NDDF |
| 387311004 | SNOMEDCT_US |
| 56059005 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| VERMOX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-675 | TABLET, CHEWABLE | 500 mg | ORAL | NDA | 27 sections |
| MEBENDAZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3732 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 21 sections |
| Emverm | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64896-669 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 26 sections |